Deflazacort vs Prednisone: Choosing a Steroid in Duchenne

Prednisone and deflazacort are the two corticosteroids most widely used to treat Duchenne muscular dystrophy, and families often want to understand the difference between them. Both slow the loss of muscle strength and prolong walking, and both are supported by years of evidence. They differ in some side effects and in cost, and the choice between them is individual.

This post compares the two in plain terms. The decision about which steroid, and at what dose, belongs to the care team.

What the two have in common

Both prednisone (given as prednisone or prednisolone) and deflazacort are corticosteroids, and both are a mainstay of Duchenne care because they slow muscle decline, help preserve walking, and protect heart and breathing muscles over time. For background on how steroids work in Duchenne, see corticosteroids in DMD.

The shared benefits are larger than the differences between them. The most important decision is usually whether to use a steroid at all, not which one.

How they compare

Head-to-head evidence suggests the two are broadly similar in their main benefits, with some differences in side-effect patterns. (Comparing Deflazacort and Prednisone in Duchenne Muscular Dystrophy, PubMed)

Commonly described differences include:

• Weight gain tends to be more pronounced with prednisone.
• Deflazacort may be associated with a higher risk of cataracts and, in some studies, a greater effect on growth.
• Mood and behaviour effects can occur with both and vary by child.

A large randomised trial comparing corticosteroid regimens in Duchenne has helped clarify the trade-offs between options. (Effect of different corticosteroid regimens on clinical outcomes in boys with Duchenne muscular dystrophy, randomized trial, PubMed)

Cost and availability

A practical difference is cost and access. Prednisone is inexpensive and available almost everywhere. Deflazacort is often more expensive and not available in every country, which can influence the choice regardless of clinical preference. For background, see DMD treatment access by country.

For many families, what is available and affordable locally shapes the decision as much as the side-effect profile.

How the choice is made

The choice depends on the individual child: their side-effect risks, growth, weight, any existing concerns, family preference, and what is available. Some teams start with one and switch if side effects become a problem.

There is no single right answer that fits every child, which is why this is a shared decision with the care team rather than a fixed rule.

Side effects matter whichever is chosen

Whichever steroid is used, the side effects need monitoring, including weight, growth, bone health, blood pressure, eyes, and adrenal function. For background, see bone health in DMD, eye care and cataract monitoring on long-term steroids in Duchenne, and adrenal insufficiency and steroid sick-day rules in Duchenne.

Steroids should also never be stopped suddenly, regardless of which one is used.

What is still uncertain

The best steroid, dose, and schedule for an individual remain areas of active study and some debate, and newer steroid-like options are changing the picture. For background, see vamorolone (Agamree) and givinostat (Duvyzat). What is consistent is that the choice is individual and best made with the care team.

For related reading, see corticosteroids in DMD, vamorolone (Agamree), bone health in DMD, eye care and cataract monitoring on long-term steroids in Duchenne, and the reported piece Two Mothers, Two Realities.

Disclaimer: This post is informational and does not constitute medical advice. Decisions about diagnosis or treatment must be made with a qualified care team.